Q32 Bio annual revenue
2018
2019
2020
2021
2022
2023
2024
2025
Q32 Bio Revenue Growth & History (QTTB)
Q32 Bio reported $53.7M in revenue for fiscal 2025.
View full Q32 Bio company overviewQ32 Bio annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $53.7M | $53.7M | — |
| 2024 | 2024-12-31 | $0 | −$1.2M | −100.00% |
| 2023 | 2023-12-31 | $1.2M | −$2.1M | −63.97% |
| 2022 | 2022-12-31 | $3.2M | −$30.8M | −90.56% |
| 2021 | 2021-12-31 | $34.0M | $31.3M | +1157.25% |
| 2020 | 2020-12-31 | $2.7M | $1.0M | +62.18% |
| 2019 | 2019-12-31 | $1.7M | −$3.7M | −68.70% |
| 2018 | 2018-12-31 | $5.3M | — | — |
Q32 Bio quarterly revenue
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | $0 | — |
| Q1 2026 | 2026-03-31 | $0 | — | — |
| Q4 2025 | 2025-12-31 | $53.7M | $53.7M | — |
| Q3 2025 | 2025-09-30 | $0 | $0 | — |
| Q2 2025 | 2025-06-30 | $0 | $0 | — |
| Q4 2024 | 2024-12-31 | $0 | $0 | — |
| Q3 2024 | 2024-09-30 | $0 | $0 | — |
| Q2 2024 | 2024-06-30 | $0 | −$354,000 | −100.00% |
| Q1 2024 | 2024-03-31 | $0 | −$802,000 | −100.00% |
| Q4 2023 | 2023-12-31 | $0 | −$802,000 | −100.00% |
| Q3 2023 | 2023-09-30 | $0 | −$802,000 | −100.00% |
| Q2 2023 | 2023-06-30 | $354,000 | −$448,000 | −55.86% |
| Q1 2023 | 2023-03-31 | $802,000 | $0 | 0.00% |
| Q4 2022 | 2022-12-31 | $802,000 | $0 | 0.00% |
| Q3 2022 | 2022-09-30 | $802,000 | −$875,000 | −52.18% |
| Q2 2022 | 2022-06-30 | $802,000 | −$1.4M | −63.33% |
| Q1 2022 | 2022-03-31 | $802,000 | −$28.5M | −97.26% |
| Q4 2021 | 2021-12-31 | $802,000 | −$178,000 | −18.16% |
| Q3 2021 | 2021-09-30 | $1.7M | $1.1M | +195.77% |
| Q2 2021 | 2021-06-30 | $2.2M | $1.6M | +285.71% |
| Q1 2021 | 2021-03-31 | $29.3M | $28.7M | +4883.84% |
| Q4 2020 | 2020-12-31 | $980,000 | $417,000 | +74.07% |
| Q3 2020 | 2020-09-30 | $567,000 | $126,000 | +28.57% |
| Q2 2020 | 2020-06-30 | $567,000 | $175,000 | +44.64% |
| Q1 2020 | 2020-03-31 | $588,000 | $318,000 | +117.78% |
| Q4 2019 | 2019-12-31 | $563,000 | −$633,000 | −52.93% |
| Q3 2019 | 2019-09-30 | $441,000 | −$1.2M | −72.47% |
| Q2 2019 | 2019-06-30 | $392,000 | −$1.0M | −71.90% |
| Q1 2019 | 2019-03-31 | $270,000 | −$859,000 | −76.09% |
| Q4 2018 | 2018-12-31 | $1.2M | — | — |
| Q3 2018 | 2018-09-30 | $1.6M | — | — |
| Q2 2018 | 2018-06-30 | $1.4M | — | — |
| Q1 2018 | 2018-03-31 | $1.1M | — | — |
Q32 Bio revenue growth trends
Over the last five reported fiscal years, revenue grew from $2.7M to $53.7M, a compound annual growth rate of 81.85%. Q32 Bio's latest reported quarter, Q2 2026, generated $0 in revenue.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Q32 Bio source filings ↗Community posts
Q32 reports maintained hair-growth responses after treatment withdrawal
Q32 Bio ($QTTB) reported new off-treatment follow-up from the open-label Part B of its SIGNAL-AA study of bempikibart for severe alopecia areata. Among 12 patients who had shown hair growth by the end of 36 weeks of treatment and entered fo ...
